Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnSquareMore
Verastem Oncology announced that its oral, potential best-in-class investigational KRAS G12D (on/off) inhibitor VS-7375 has received Fast Track designation from the U.S. Food and Drug Administration (FDA).

Verastem Oncology announced that its oral, potential best-in-class investigational KRAS G12D (on/off) inhibitor VS-7375 has received Fast Track designation from the U.S. Food and Drug Administration (FDA).

老虎证券老虎证券2026/06/03 20:06
Show original
This medication is intended for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) carrying the KRAS G12D mutation. Fast Track designation is designed to accelerate the development and review process for drugs aimed at serious conditions that address unmet medical needs. This designation means that VS-7375 has the potential to address the critical clinical need in KRAS G12D-mutant NSCLC. For Verastem, this represents an important regulatory milestone in advancing its product pipeline.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Nvidia quietly reduces OpenAI data center guarantee from 250 billions to below 120 billions

Nvidia and OpenAI are close to signing a data center financing agreement in Ohio. However, Nvidia's financial guarantee has been reduced from $250 billion to less than $120 billion, covering only about 5 GW of computing power for the project's first phase. This adjustment is a direct response to investor concerns about Nvidia's risk exposure—after the previous $250 billion guarantee plan was revealed, Nvidia's stock price fell 5% in a single day. The agreement could be signed as early as this weekend.

华尔街见闻2026/08/16 04:06